ERK5 Signalling in Prostate Cancer Promotes an Invasive Phenotype

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Jan 27

PMID 21266977

Citations 46

Authors

A K Ramsay

S R C McCracken

M Soofi

J FLEMING

A X Yu

I Ahmad

R Morland

L Machesky

C Nixon

D R Edwards

R K Nuttall

M Seywright

R Marquez

E Keller

H Y Leung

Affiliations

Soon will be listed here.

Abstract

Background: Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)-extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (PCa). The molecular basis of ERK5-driven carcinogenesis and its clinical relevance remain to be fully characterised.

Methods: Modulation of ERK5 expression or function in human PCa PC3 and PC3-ERK5 (stably transfected with ERK5) cells was performed using siRNA-mediated knockdown or the MEK inhibitor PD18435 respectively. In vitro significance of ERK5 signalling was assessed by assays for proliferation, motility, invasion and invadopodia. Expression of matrix metalloproteinases/tissue inhibitors of metalloproteases was determined by Q-RT-PCR. Extracellular signal-regulated protein kinase 5 expression in primary and metastatic PCa was examined using immunohistochemistry.

Results: Reduction of ERK5 expression or signalling significantly inhibited the motility and invasive capability of PC3 cells. Extracellular signal-regulated protein kinase 5-mediated signalling significantly promoted formation of in vivo metastasis in an orthotopic PCa model (P<0.05). Invadopodia formation was also enhanced by forced ERK5 expression in PC3 cells. Furthermore, in metastatic PCa, nuclear ERK5 immunoreactivity was significantly upregulated when compared with benign prostatic hyperplasia and primary PCa (P=0.013 and P<0.0001, respectively).

Conclusion: Our in vitro, in vivo and clinical data support an important role for the MEK5-ERK5 signalling pathway in invasive PCa, which represents a potential target for therapy in primary and metastatic PCa.

Citing Articles

The impact of dysregulation SUMOylation on prostate cancer.

Li K, Wang H, Jiang B, Jin X J Transl Med. 2025; 23(1):286.

PMID: 40050932 PMC: 11887156. DOI: 10.1186/s12967-025-06271-2.

Bone and Extracellular Signal-Related Kinase 5 (ERK5).

Wen L, Liu Z, Zhou L, Liu Z, Li Q, Geng B Biomolecules. 2024; 14(5).

PMID: 38785963 PMC: 11117709. DOI: 10.3390/biom14050556.

The significance of ERK5 catalytic-independent functions in disease pathways.

Le N Front Cell Dev Biol. 2023; 11:1235217.

PMID: 37601096 PMC: 10436230. DOI: 10.3389/fcell.2023.1235217.

Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation.

You I, Donovan K, Krupnick N, Boghossian A, Rees M, Ronan M Cell Chem Biol. 2022; 29(11):1630-1638.e7.

PMID: 36220104 PMC: 9675722. DOI: 10.1016/j.chembiol.2022.09.004.

OXTR stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling.

Ding L, Fu Y, Zhu N, Zhao M, Ding Z, Zhang X Nat Commun. 2022; 13(1):5124.

PMID: 36045118 PMC: 9433374. DOI: 10.1038/s41467-022-32787-y.

References

Clark I, Swingler T, Sampieri C, Edwards D . The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008; 40(6-7):1362-78. DOI: 10.1016/j.biocel.2007.12.006. View

Ayala I, Baldassarre M, Giacchetti G, Caldieri G, Tete S, Luini A . Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J Cell Sci. 2008; 121(Pt 3):369-78. DOI: 10.1242/jcs.008037. View

Troussard A, Costello P, Yoganathan T, Kumagai S, Roskelley C, Dedhar S . The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene. 2000; 19(48):5444-52. DOI: 10.1038/sj.onc.1203928. View

Sharma G, Goalstone M . Dominant negative FTase (DNFTalpha) inhibits ERK5, MEF2C and CREB activation in adipogenesis. Mol Cell Endocrinol. 2005; 245(1-2):93-104. DOI: 10.1016/j.mce.2005.10.027. View

Dong Z, Nemeth J, Cher M, Palmer K, Bright R, Fridman R . Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer. 2001; 93(4):507-15. DOI: 10.1002/ijc.1358. View

Mehta P, Jenkins B, McCarthy L, Thilak L, Robson C, Neal D . MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene. 2003; 22(9):1381-9. DOI: 10.1038/sj.onc.1206154. View

Zen K, Yasui K, Nakajima T, Zen Y, Zen K, Gen Y . ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes Chromosomes Cancer. 2008; 48(2):109-20. DOI: 10.1002/gcc.20624. View

McCracken S, Ramsay A, Heer R, Mathers M, Jenkins B, Edwards J . Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene. 2007; 27(21):2978-88. DOI: 10.1038/sj.onc.1210963. View

Trudel D, Fradet Y, Meyer F, Harel F, Tetu B . Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 2003; 63(23):8511-5. View

10.

Wang X, Tournier C . Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal. 2005; 18(6):753-60. DOI: 10.1016/j.cellsig.2005.11.003. View

11.

Riddick A, Shukla C, Pennington C, Bass R, Nuttall R, Hogan A . Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer. 2005; 92(12):2171-80. PMC: 2361819. DOI: 10.1038/sj.bjc.6602630. View

12.

Wang X, Merritt A, Seyfried J, Guo C, Papadakis E, Finegan K . Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol. 2004; 25(1):336-45. PMC: 538774. DOI: 10.1128/MCB.25.1.336-345.2005. View

13.

Ricca A, Biroccio A, Del Bufalo D, Mackay A, Santoni A, Cippitelli M . bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer. 2000; 86(2):188-96. DOI: 10.1002/(sici)1097-0215(20000415)86:2<188::aid-ijc7>3.0.co;2-w. View

14.

Mody N, Leitch J, Armstrong C, DIXON J, Cohen P . Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 2001; 502(1-2):21-4. DOI: 10.1016/s0014-5793(01)02651-5. View

15.

Udayakumar T, Chen M, Bair E, Von Bredow D, Cress A, Nagle R . Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res. 2003; 63(9):2292-9. View

16.

Sternlicht M, Werb Z . How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17:463-516. PMC: 2792593. DOI: 10.1146/annurev.cellbio.17.1.463. View

17.

Sato H, Seiki M . Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene. 1993; 8(2):395-405. View

18.

Ramsay A, Leung H . Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clin Sci (Lond). 2009; 117(6):209-28. DOI: 10.1042/CS20080391. View

19.

Ranganathan A, Pearson G, Chrestensen C, Sturgill T, Cobb M . The MAP kinase ERK5 binds to and phosphorylates p90 RSK. Arch Biochem Biophys. 2006; 449(1-2):8-16. DOI: 10.1016/j.abb.2006.02.023. View

20.

Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli M . Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010; 18(3):258-67. PMC: 2939729. DOI: 10.1016/j.ccr.2010.08.008. View